Skip to main content

Security report for biogen-poland.pl

Biogen Poland Sp. z o.o. · Healthcare · Poland

Low risk. 2 critical or high findings in Email security and SSL/TLS.

Security score

82/100

Risk levelLow

0–100, higher is better. How it is calculated

Biogen Poland Sp. z o.o. operates as a local subsidiary of the global biotechnology leader Biogen, focusing on innovative therapies in neurology, neuropsychiatry, immunology, and rare diseases. The website targets Polish users with comprehensive information about the company, its therapeutic areas, career opportunities, and corporate responsibility. The digital infrastructure is built on Adobe Experience Manager, leveraging modern web technologies including jQuery, Cookiebot for consent management, and Google Analytics for user insights. The site is well-structured, mobile-optimized, and compliant with GDPR regulations, featuring clear cookie and privacy policies. Security posture is strong with HTTPS enforced and secure cookie practices, though some security headers could be improved. WHOIS data is unavailable due to registry restrictions, but the site’s professional presentation and linkage to Biogen’s global domains support its legitimacy.

Scanned

NIS2 and GDPR posture

GDPR outside view
88/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching biogen-poland.pl

This scan found 16 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
72
Security headers
95
Email security
60
DNS health
75
Network security
100
GDPR outside view
88
Average
82

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Biogen Poland is positioned as a key regional player within the global Biogen group, focusing on high-need therapeutic areas. The business model centers on research-driven pharmaceutical development and patient-centric innovation. The website reflects a mature digital presence with clear branding and compliance adherence, supporting trust and engagement with healthcare professionals and patients. The company maintains active social media channels and provides career information, indicating growth and talent acquisition focus. Absence of direct contact emails or phone numbers on the homepage suggests controlled communication channels, likely via contact forms. The site links extensively to other Biogen regional domains, indicating a broad partnership and subsidiary network.

Security posture

The website demonstrates a solid security foundation with HTTPS, secure cookies, and a comprehensive cookie consent mechanism. However, explicit security policies, incident response contacts, and vulnerability disclosure mechanisms are not present, representing areas for improvement. No critical vulnerabilities or exposed sensitive data were detected. The use of third-party scripts like Google Analytics and Cookiebot is managed with user consent, aligning with privacy best practices. The lack of security headers such as Content-Security-Policy and X-Frame-Options could be addressed to enhance protection against common web attacks. Overall, the security posture is good but could benefit from formalized policies and additional technical controls.

Recommendations

  1. Implement comprehensive security headers including Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options.
  2. Publish explicit security and incident response policies on the website to improve transparency and readiness.
  3. Introduce a security.txt file to facilitate responsible vulnerability disclosure.
  4. Enhance accessibility features to meet higher compliance standards and improve user experience for all users.
  5. Regularly audit and update third-party scripts and libraries to mitigate potential vulnerabilities.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Biogen Poland Sp. z o.o.
Description
Biogen jest wiodącą globalną firmą biotechnologiczną, która jako pionier w dziedzinie nauki opracowuje innowacyjne metody leczenia złożonych i wyniszczających chorób. Biogen rozwija szereg potencjalnych terapii w obszarze neurologii, neuropsychiatrii, immunologii i chorób rzadkich oraz nieustannie dąży do realizacji swojego celu, jakim jest służenie ludzkości poprzez naukę, przy jednoczesnym wspieraniu zdrowszego, bardziej zrównoważonego i sprawiedliwego świata.
Key services
development of therapies in neurology, neuropsychiatry, immunology, rare diseases
Content quality
good
Branding
consistent

Technology

Stack
jQuery 3.6.4, Adobe Helix RUM, Cookiebot, Google Tag Manager, Google Analytics, Video.js
Frameworks
Adobe Experience Manager (AEM)
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent mechanism implemented
  • Use of httpOnly cookies for security
  • Load balancing cookies for performance

Analytics and tracking

Services
Google Analytics
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Cookiebot session tracker
Marketing tools
Cookiebot
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with no blocking or WAF challenges.
  2. Content is professionally presented in Polish targeting Polish audience.
  3. Strong compliance with GDPR and cookie consent regulations.
  4. No direct contact emails or phone numbers found on homepage; contact form available.
  5. Use of modern web technologies and Adobe Experience Manager CMS.
  6. Social media presence linked to official Biogen accounts.
  7. No security.txt or explicit security policy pages found.
  8. WHOIS data unavailable, typical for .pl domains with privacy protection or registry restrictions.
Technical notes

Notes

The website is built on Adobe Experience Manager, a robust enterprise CMS platform, ensuring scalability and content management efficiency. The tech stack includes modern JavaScript libraries such as jQuery 3.6.4 and Video.js for media handling. Cookiebot is integrated for GDPR-compliant cookie management, and Google Tag Manager facilitates analytics and marketing tags. Performance is moderate with asynchronous script loading and responsive design for mobile devices. SEO is supported by proper meta tags and Open Graph data. Some technical debt is noted in the absence of advanced security headers and limited accessibility features. Hosting details are not explicitly identified but likely managed by enterprise-grade providers given the CMS choice.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with biogen-poland.pl. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review biogen-poland.pl.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.